Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefprozil is a semisynthetic, second-generation cephalosporin antibiotic used to treat a variety of bacterial infections, including pharyngitis, tonsillitis, otitis media (middle ear infection), sinusitis, bronchitis, and skin or soft tissue infections. It acts by binding to specific penicillin-binding proteins (PBPs) inside the bacterial cell wall and inhibiting the final stage of cell wall synthesis. This leads to cell lysis mediated by autolytic enzymes within the bacteria. Cefprozil is administered orally as tablets or suspension and is effective against a broad range of gram-positive and some gram-negative bacteria[1][2][3][4][5][6]. It does not work for viral infections such as colds or flu.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefprozil.